Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 7/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93046 | 0.88 | MAPT (0.63) | MAPTPOLBTP53SMN1; SMN2LMNA | |
| SCHEMBL14626973 | 0.85 | MAPT (0.55) | MAPTPOLBTP53RXFP1SMN1; SMN2 | |
| SCHEMBL92550 | 0.84 | MAPT (0.59) | MAPTPOLBTP53SMN1; SMN2LMNA | |
| SCHEMBL92544 | 0.83 | MAPT (0.58) | MAPTPOLBTP53RXFP1SMN1; SMN2 | |
| SCHEMBL14591884 | 0.83 | MAPT (0.54) | MAPTPOLBTP53RXFP1SMN1; SMN2 | |
| SCHEMBL91670 | 0.79 | PIN1 (0.53) | MAPTPOLBTP53RXFP1SMN1; SMN2 | |
| SCHEMBL92212 | 0.78 | HIF1A (0.68) | MAPTTP53 | |
| SCHEMBL92276 | 0.78 | KMT2A (0.44) | MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL91598 | 0.77 | KDM4E (0.51) | MAPT | |
| SCHEMBL92534 | 0.76 | MAPT (0.65) | MAPTPOLBTP53SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAPT 4775/4885POLB 3346/4885TP53 4440/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | MAPT 4773/4885POLB 3839/4885TP53 4330/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAPT 4795/4885POLB 3232/4885TP53 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.